Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride)
(Synonyms: 丙酰左旋肉碱盐酸盐; L-Propionylcarnitine chloride; ST-261) 目录号 : GC30373
A carnitine derivative
Cas No.:119793-66-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Propionyl-L-carnitine is a naturally occurring carnitine derivative formed by carnitine acetyltransferase during β-oxidation of uneven chain fatty acids.1 Propionyl-L-carnitine increases the basal release of prostaglandin E2 and 6-keto-prostaglandin F1α in carrageenan-stimulated isolated rat peritoneal cells contaminated with neutrophils and increases the basal release of thromboxane B2 in non-contaminated cells.1 It reduces the production of reactive oxygen species (ROS) and decreases the expression of NADPH oxidase 2 (NOX2), NOX4, and ICAM-1 in human umbilical vein endothelial cells (HUVECs). It also increases the rate of revascularization and the hind limb vascular area in a rabbit model of hind limb ischemia when administered at a dose of 10 mg per animal.2 Propionyl-L-carnitine reduces mitochondrial dysfunction induced by ischemia, preventing mitochondrial calcium overload, and depletion of ATP tissue stores in a rabbit model of ischemia.3
1.Garrelds, I.M., Elliott, G.R., Pruimboom, W.M., et al.Effects of carnitine and its congeners on eicosanoid discharge from rat cells: Implications for release of TNFαMediators Inflamm.2(7)S57-S62(1993) 2.Stasi, M.A., Scioli, M.G., Arcuri, G., et al.Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide productionArterioscler. Thromb. Vasc. Biol.30(3)426-435(2010) 3.Ferrari, R., Ceconi, C., Cargnoni, A., et al.The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondriaCardiovasc. Drugs Ther.5 (Suppl 1)57-65(1991)
| Cas No. | 119793-66-7 | SDF | |
| 别名 | 丙酰左旋肉碱盐酸盐; L-Propionylcarnitine chloride; ST-261 | ||
| Canonical SMILES | CCC(O[C@H](CC(O)=O)C[N+](C)(C)C)=O.[Cl-] | ||
| 分子式 | C10H20ClNO4 | 分子量 | 253.72 |
| 溶解度 | DMSO : 150 mg/mL (591.20 mM);Water : 60 mg/mL (236.48 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9414 mL | 19.7068 mL | 39.4135 mL |
| 5 mM | 0.7883 mL | 3.9414 mL | 7.8827 mL |
| 10 mM | 0.3941 mL | 1.9707 mL | 3.9414 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet